1051 related articles for article (PubMed ID: 27208375)
21. Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial.
McGuire DK; Zinman B; Inzucchi SE; Wanner C; Fitchett D; Anker SD; Pocock S; Kaspers S; George JT; von Eynatten M; Johansen OE; Jamal W; Mattheus M; Elsasser U; Hantel S; Lund SS
Lancet Diabetes Endocrinol; 2020 Dec; 8(12):949-959. PubMed ID: 33217335
[TBL] [Abstract][Full Text] [Related]
22. Revitalization of pioglitazone: the optimum agent to be combined with a sodium-glucose co-transporter-2 inhibitor.
DeFronzo RA; Chilton R; Norton L; Clarke G; Ryder RE; Abdul-Ghani M
Diabetes Obes Metab; 2016 May; 18(5):454-62. PubMed ID: 26919068
[TBL] [Abstract][Full Text] [Related]
23. [EMPAGLIFLOZIN (JARDIANCE) :Nw SGLT2 COTRANSPORTER INHIBITOR FOR TREATING TYPE 2 DIABETES].
Scheen AJ
Rev Med Liege; 2015 Sep; 70(9):472-9. PubMed ID: 26638450
[TBL] [Abstract][Full Text] [Related]
24. Can a Shift in Fuel Energetics Explain the Beneficial Cardiorenal Outcomes in the EMPA-REG OUTCOME Study? A Unifying Hypothesis.
Mudaliar S; Alloju S; Henry RR
Diabetes Care; 2016 Jul; 39(7):1115-22. PubMed ID: 27289124
[TBL] [Abstract][Full Text] [Related]
25. Impact of empagliflozin in patients with diabetes and heart failure.
Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
[TBL] [Abstract][Full Text] [Related]
26. Relationship between hypoglycaemia, cardiovascular outcomes, and empagliflozin treatment in the EMPA-REG OUTCOME® trial.
Fitchett D; Inzucchi SE; Wanner C; Mattheus M; George JT; Vedin O; Zinman B; Johansen OE
Eur Heart J; 2020 Jan; 41(2):209-217. PubMed ID: 31504427
[TBL] [Abstract][Full Text] [Related]
27. Class effects of SGLT2 inhibitors on cardiorenal outcomes.
Kluger AY; Tecson KM; Lee AY; Lerma EV; Rangaswami J; Lepor NE; Cobble ME; McCullough PA
Cardiovasc Diabetol; 2019 Aug; 18(1):99. PubMed ID: 31382965
[TBL] [Abstract][Full Text] [Related]
28. Implications of the EMPA-REG Trial for Clinical Care and Research.
Stamatouli AM; Inzucchi SE
Curr Diab Rep; 2016 Dec; 16(12):131. PubMed ID: 27812962
[TBL] [Abstract][Full Text] [Related]
29. Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial.
Fitchett D; Butler J; van de Borne P; Zinman B; Lachin JM; Wanner C; Woerle HJ; Hantel S; George JT; Johansen OE; Inzucchi SE;
Eur Heart J; 2018 Feb; 39(5):363-370. PubMed ID: 29020355
[TBL] [Abstract][Full Text] [Related]
30. EMPA-REG OUTCOME: The Cardiologist's Point of View.
Pham SV; Chilton RJ
Am J Cardiol; 2017 Jul; 120(1S):S53-S58. PubMed ID: 28606345
[TBL] [Abstract][Full Text] [Related]
31. Sodium-glucose cotransporter 2 inhibitors and cardiovascular outcomes.
Steinberg HO
Postgrad Med; 2016 May; 128(4):398-408. PubMed ID: 26999348
[TBL] [Abstract][Full Text] [Related]
32. [EMPA-REG OUTCOME: Empagliflozin reduces mortality in patients with type 2 diabetes at high cardiovascular risk].
Scheen AJ
Rev Med Liege; 2015 Nov; 70(11):583-9. PubMed ID: 26738271
[TBL] [Abstract][Full Text] [Related]
33. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
34. Empagliflozin and Cardiovascular Outcomes in Asian Patients With Type 2 Diabetes and Established Cardiovascular Disease - Results From EMPA-REG OUTCOME
Kaku K; Lee J; Mattheus M; Kaspers S; George J; Woerle HJ;
Circ J; 2017 Jan; 81(2):227-234. PubMed ID: 28025462
[TBL] [Abstract][Full Text] [Related]
35. The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease.
Kaku K; Wanner C; Anker SD; Pocock S; Yasui A; Mattheus M; Lund SS
Diabetes Obes Metab; 2022 Apr; 24(4):662-674. PubMed ID: 34908223
[TBL] [Abstract][Full Text] [Related]
36. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes.
Dziuba J; Alperin P; Racketa J; Iloeje U; Goswami D; Hardy E; Perlstein I; Grossman HL; Cohen M
Diabetes Obes Metab; 2014 Jul; 16(7):628-35. PubMed ID: 24443793
[TBL] [Abstract][Full Text] [Related]
37. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus.
Pancholia AK
Indian Heart J; 2018; 70(6):915-921. PubMed ID: 30580866
[TBL] [Abstract][Full Text] [Related]
38. Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.
Lytvyn Y; Bjornstad P; Udell JA; Lovshin JA; Cherney DZI
Circulation; 2017 Oct; 136(17):1643-1658. PubMed ID: 29061576
[TBL] [Abstract][Full Text] [Related]
39. Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review.
Yankah RK; Anku EK; Eligar V
J Diabetes Res; 2024; 2024():9985836. PubMed ID: 38766320
[No Abstract] [Full Text] [Related]
40. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
